Diagnostics
Beyond the Lab: 4 Startups Moving Testing Closer to Patients
DealBio tracks early-stage testing and monitoring startups across Europe and North America. These 4 are moving useful measurements closer to patients through simpler sampling, home monitoring and point-of-care readouts.
- Diagnostics
- Point-of-Care
- Biomarkers
- Remote Monitoring
Diagnostics and monitoring are becoming more flexible as new products make samples easier to collect, results faster to access and measurements possible in more settings.
These startups redesign different parts of the measurement pathway: the sample itself, the readout or the location where monitoring happens. Each brings information closer to the moment when a patient or clinician can act on it.
At a Glance
- Capillon AnalyticsSweden2024Hair-sample cancer testing
- Dx4LifeSweden2024Rapid genetic testing in IVF
- PrecorDxNetherlands2023Home heart-function monitoring
- Beyond DiagnosticsSwitzerland2026Point-of-care insulin testing
Developing a hair-sample test for early prostate cancer detection.
- Country
Sweden- Founded
- 2024
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
- Founders
Why Capillon Analytics stands out
Capillon Analytics reported approximately 90% accuracy for its prostate-cancer prototype, while related Prostate Cancer Foundation-backed research reported about 94% accuracy in preliminary work.
The underlying research has received Prostate Cancer Foundation support, and a 2026 patent application covers isotopic hair or nail analysis combined with machine learning for cancer detection.
What Capillon Analytics is building
IsoTect is a hair-based test intended to complement PSA testing before biopsy. Capillon Analytics’ Lund laboratory measures stable-isotope patterns by mass spectrometry and applies machine learning to identify signals associated with prostate cancer.
The patient-facing shift is in sampling: hair can be collected away from a specialist facility, even though the analysis remains centralized in Capillon Analytics’ laboratory.
02
Dx4Life
Developing a rapid swab test to match IVF hormone treatment to a woman's genetics.
- Country
- Sweden
- Founded
- 2024
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
- Founders
Why Dx4Life stands out
Dx4Life raised SEK 6.4 million in its first round, led by Gobia Enterprises, and has filed an international patent application for Dx4IVF.
The test addresses a decision made before ovarian stimulation begins, giving the startup a defined place in an existing IVF workflow rather than creating a separate diagnostic pathway.
What Dx4Life is building
Dx4IVF is a cheek-swab test that reads a genetic variant in the receptor carrying the hormone signal to the ovaries. The clinic receives a visible result in under an hour.
The result is designed to be available during the same appointment, moving genetic testing closer to the moment when the clinician chooses the hormone treatment.
03
PrecorDx
Developing a wearable radio-frequency sensor for home heart-function monitoring.
- Country
Netherlands- Founded
- 2023
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why PrecorDx stands out
PrecorDx combines university-developed radio-frequency sensing with human-study results and founders experienced in cardiovascular research, imaging and commercialization.
The startup has received NWO Take-off and Health~Holland support and has moved into clinical pilot work, giving the sensing approach a route from academic research toward repeated home use.
What PrecorDx is building
PrecorDx is developing a wearable radio-frequency system that tracks cardiac and respiratory motion from the chest without repeated blood draws or an implantable sensor.
The product moves heart-function monitoring into the home, giving clinicians a denser view of changes between clinic visits rather than relying only on periodic in-clinic measurements.
Building smartphone-read tests to verify insulin activity before injection.
- Country
Switzerland- Founded
- 2026
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
- Founders
Why Beyond Diagnostics stands out
Beyond Diagnostics is part of a CHF659,000 Innosuisse-supported project with CSEM and built its first functional insulin-activity prototype in 2026. Its underlying in-vitro activity assay was validated in 2025.
Founder Maren Schinz previously built a diabetes startup that reached more than 2,000 customers in its first year and led the insulin-activity work before spinning it into Beyond Diagnostics.
What Beyond Diagnostics is building
LUMIQ is a point-of-care lateral-flow test designed to estimate remaining insulin activity before injection. A smartphone camera reads the disposable strip and AI interprets the optical signal.
The test moves the quality check to the point of use, so patients can assess whether the insulin remains active immediately before injection rather than relying only on storage history.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Moving the measurement can change the workflow
The shared opportunity is not simply a smaller device or easier sample. Each startup moves a useful measurement closer to the decision it informs: whether to investigate a cancer signal, select an IVF hormone, monitor heart failure or verify insulin before use.
For investors, that can matter because changing where a measurement happens can also change how often it is used and how quickly someone can act on it. Accuracy still has to hold up, but workflow fit becomes part of the product value rather than a secondary convenience.
Methodology
DealBio selected these startups from its database of early-stage health and longevity startups, focusing on businesses that bring testing or monitoring closer to patients and care decisions. The selection spans non-invasive sampling, rapid genetic testing, wearable sensing and point-of-care medication-quality testing.
DealBio builds its Startup Briefs using publicly available company materials, ecosystem sources, market references and professional profiles.